Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | Retatrutide is the ultimate triple-threat for weight loss. It tells your brain you are full, tells your stomach to stop eating, AND cranks up your metabolism to burn off massive amounts of fat faster than anything else. | Cagrilintide sends a powerful "I am totally full" signal to your brain. It acts just like a hormone your body makes when you eat a huge meal, making you feel satisfied and completely uninterested in food for a long time. |
Studied For | Obesity / overweightType 2 diabetesLiver fat / MASLD / NAFLDTriple agonist weight lossGLP-1 GIP glucagon combined therapyMetabolic syndromeInsulin resistanceHbA1c reductionCardiovascular risk reductionNon-alcoholic steatohepatitis (NASH)Body weight reduction vs placeboAppetite suppression triple pathwayLean mass preservation during weight lossObstructive sleep apnea in obesityextreme weight lossobesityliver fat reductionNAFLDmetabolic rate increaseappetite suppressionlipid lowering | Obesity / overweightType 2 diabetesCombination with semaglutide (CagriSema)Amylin receptor agonism for satietyCaloric intake reductionBody weight reductionGlucagon suppressionGastric emptying delayAmylin-mediated satiety signalingCardiometabolic risk reductionInsulin sensitivity improvementMetabolic syndromeweight losssatietyappetite suppressiongastric emptying slowingobesity |
Research Areas | MetabolicWeight Management & Fat Loss | MetabolicWeight Management & Fat Losshormonal |
Best Stacked With | l-carnitineb12bac-water | semaglutidebac-water |
Overview | ||
Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
Compound Class | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor | Long-acting synthetic amylin analog (fatty acid-conjugated for once-weekly dosing) |
Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect | Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation |
Aliases / AKA | LY-3437943Triple-GRetatrutide peptideLY3437943Triple agonist obesity drugGIP GLP-1 glucagon triple agonist | AM833Cagrilintide AM833Long-acting amylin analogAmylin receptor agonistCalcitonin receptor agonist obesityAmylin obesity peptide |
Parent Compound | Incretin triple agonist | Human amylin |
Molecular Weight | 4731.3 Da | 4409.01 Da |
Amino Acid Sequence | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) | acylated cyclic amylin analog |
CAS Number | 2381089-83-2 | 1415456-99-3 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 306 Good | 80 Moderate |
Clinical Trials | 1515 Active | 2222 Active |
Regulatory Status | Investigational (Eli Lilly); Phase 3 TRIUMPH program -- TRIUMPH-1 topline results reported May 2026 (2,339 participants, 80 wk; -28.3% mean weight loss at 12 mg; all three doses met primary and key secondary endpoints vs placebo); NDA submission expected Q4 2026 to Q1 2027; FDA decision projected 2027 or later; not FDA-approved; non-trial material research-use-only. | Investigational (Novo Nordisk); not FDA-approved. |
Evidence & Regulatory | ||
Half-Life | ~1 week | ~1 week (weekly SC, acylated) |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | A Phase 2 trial reported up to about 17.5 percent weight reduction at 24 weeks and more at 48 weeks; Phase 3 is ongoing. | A Phase 2 dose-finding trial showed roughly 10.8 percent weight reduction at 26 weeks with the highest dose versus about 3 percent for placebo; development is most advanced in combination with semaglutide. |
Side Effects Noted | Dose-dependent gastrointestinal effects (nausea, vomiting, diarrhea), fatigue, mild heart-rate increases. | Predominantly gastrointestinal effects (nausea, vomiting), mild to moderate and dose-dependent; injection-site reactions. |
Warnings | Investigational with no approved label or long-term safety data; theoretical thyroid C-cell and pancreatitis considerations under study. Research use only. | Investigational with no approved indication; long-term safety not established. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | bacteriostatic or sterile water; gentle | bacteriostatic or sterile water |
Storage Temp | frozen/refrigerated, dark | frozen/refrigerated, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Lipidated peptide; gentle reconstitution avoids foaming. | Cyclic disulfide; avoid reducing conditions. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
